Closing the HPV Testing Gap Act

If this bill passes, the NIH will spend 24-30 months developing recommendations for a male HPV test—a test that currently does not exist in FDA-approved form. This could lead to regulatory submissions to the FDA and eventual commercialization of new diagnostic tests. Analogous precedent: the HPV vaccine (Gardasil), approved for men in 2009, was subsequently recommended by the CDC for routine male adolescent vaccination starting in 2011, expanding the vaccine market and reducing HPV transmission across both sexes over time. However, vaccination uptake has remained suboptimal (approximately 75% of adolescent girls and 64% of adolescent boys as of 2022), suggesting that availability does not automatically translate to population uptake. Male HPV screening at scale would require parallel infrastructure changes (training of providers, patient awareness, integration into screening protocols), analogous to the rollout of cervical HPV testing that began replacing Pap smears in the 2000s. The bill's explicit focus on equitable access and underserved communities suggests potential for reducing disparities in cancer outcomes, though implementation success depends on resources allocated at state and local levels post-study.